R01 MH073676/MH/NIMH NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2008	1
2009	5
2010	3
2011	1
2012	16
2013	9
2014	11
2015	9
2016	13
2017	11
2018	4
2019	4
2021	1
2022	0

1

Targeting muscarinic receptors to treat schizophrenia.

Foster DJ, Bryant ZK, Conn PJ. Foster DJ, et al. Behav Brain Res. 2021 May 7;405:113201. doi: 10.1016/j.bbr.2021.113201. Epub 2021 Feb 26. Behav Brain Res. 2021. PMID: 33647377 Free PMC article. Review.

2

Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Moran SP, Maksymetz J, Conn PJ. Moran SP, et al. Trends Pharmacol Sci. 2019 Dec;40(12):1006-1020. doi: 10.1016/j.tips.2019.10.007. Epub 2019 Nov 8. Trends Pharmacol Sci. 2019. PMID: 31711626 Free PMC article. Review.

3

The antipsychotic potential of muscarinic allosteric modulation.

Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, Lindsley CW. Bridges TM, et al. Drug News Perspect. 2010 May;23(4):229-40. doi: 10.1358/dnp.2010.23.4.1416977. Drug News Perspect. 2010. PMID: 20520852 Free PMC article. Review.

4

Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.

Conn PJ, Lindsley CW, Meiler J, Niswender CM. Conn PJ, et al. Nat Rev Drug Discov. 2014 Sep;13(9):692-708. doi: 10.1038/nrd4308. Nat Rev Drug Discov. 2014. PMID: 25176435 Free PMC article. Review.

5

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA. Menniti FS, et al. Curr Top Med Chem. 2013;13(1):26-54. doi: 10.2174/1568026611313010005. Curr Top Med Chem. 2013. PMID: 23409764 Free PMC article. Review.

6

Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Nickols HH, Conn PJ. Nickols HH, et al. Neurobiol Dis. 2014 Jan;61:55-71. doi: 10.1016/j.nbd.2013.09.013. Epub 2013 Sep 27. Neurobiol Dis. 2014. PMID: 24076101 Free PMC article. Review.

7

Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.

Noetzel MJ, Jones CK, Conn PJ. Noetzel MJ, et al. Discov Med. 2012 Nov;14(78):335-43. Discov Med. 2012. PMID: 23200065 Free PMC article. Review.

8

Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?

Gogliotti RG, Conn PJ. Gogliotti RG, et al. Neuropsychopharmacology. 2016 Jan;41(1):376-7. doi: 10.1038/npp.2015.259. Neuropsychopharmacology. 2016. PMID: 26657955 Free PMC article. Review. No abstract available.

9

Roles of the M₄ acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Moehle MS, Conn PJ. Moehle MS, et al. Mov Disord. 2019 Aug;34(8):1089-1099. doi: 10.1002/mds.27740. Epub 2019 Jun 18. Mov Disord. 2019. PMID: 31211471 Free PMC article. Review.

10

Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.

Foster DJ, Jones CK, Conn PJ. Foster DJ, et al. Discov Med. 2012 Dec;14(79):413-20. Discov Med. 2012. PMID: 23272693 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results